Hepatitis C

Principles of Gastroenterology for the NP and PA

Aug. 11, 2017

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

Payer and Provider Workshops in HCV and HIV (New York, NY)

June 13, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free evening program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management.

Payer and Provider Workshops in HCV and HIV (Newark, NJ)

June 12, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free evening program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management.

Payer and Provider Workshops in HCV and HIV (Washington, DC)

June 8, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free evening program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management.

Payer and Provider Workshops in HCV and HIV (Minneapolis, MN)

June 6, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free evening program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management.

Payer and Provider Workshops in HCV and HIV (Boston, MA)

June 5, 2017

Join AGA, PRIME and the Academy of Managed Care Pharmacy at a free evening program that reflects the most relevant and difficult issues in HCV and HIV treatment and patient management.

HCV Rare in Kids; Treatment Isn't Straightforward

May 11, 2017

DAAs may be around the corner for children, but many considerations remain. More insights in this AGA-MedPage Today Reading Room article.
Advertisement

New Hep C Tx Can Cure Most Patients

April 27, 2017

Direct-acting antivirals are effective, but more access is needed. More insights in this AGA-MedPage Today Reading Room article.

Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection

April 25, 2017

For treatment-naïve and -experienced patients, ledipasvir–sofosbuvir for 12 weeks is highly effective for the treatment of HCV genotype 2.

Liver & Biliary Sessions Scheduled at DDW® 2017

April 17, 2017

Council leadership hand-picked a preview of sessions for you to add to your DDW® itinerary.

HCV Moving Closer to Eradication

April 14, 2017

Funding, lower drug costs could win fight against HCV. Read more in this AGA-MedPage Today Reading Room article.

Counseling Helps Keep HCV Treatment on Track

April 3, 2017

Many resources available for caregivers and patients, according to this AGA-MedPage Today Reading Room article.

Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation

April 1, 2017

We compared data on disease prevalence in the population with data from liver transplantation waitlists.

High Cure Rates for HCV Patients Undergoing Liver Transplant with New DAAs

March 30, 2017

Indications that post-transplant treatment should start sooner rather than later - read more in the AGA-MedPage Today Reading Room.

Earn CME Credit in the March Journals

March 27, 2017

The three March CME quizzes cover celiac disease, hepatitis C and defecatory disorders.

New HCV Treatments Work Well for Severe Liver Disease

March 21, 2017

New therapies are safe and effective in patients with decompensated cirrhosis. Find out more in the AGA-MedPage Today Reading Room.

Unrestricted DAA Access Halved Dutch HCV Incidence in HIV

March 6, 2017

GI & Hepatology News reports on a new study finding that new hepatitis C infections among HIV-positive men were halved in the Netherlands by unrestricted access to direct-acting antivirals.

Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis

March 1, 2017

Drs. Drenth and Berden discuss their manuscript "Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis." To view abstract click http://bit.ly/2m9bXGa.

HCV Genotype 1 No Longer a Treatment Bugbear

Feb. 17, 2017

While treatment failure is rare, there are therapy nuances. Article discusses in the AGA MedPage Today Reading Room.

Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation

Feb. 1, 2017

We investigated whether patients who maintained SVR12 with DAA agents after liver transplantation had occult HCV infections.

Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities

Feb. 1, 2017

We conducted a phase 4, open-label study with limited exclusion criteria to evaluate the safety and efficacy of sofosbuvir and ribavirin in veterans with hepatitis C virus genotype 2 infection, and compensated cirrhosis.

Eradication of HCV in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications

Jan. 23, 2017

This MedPage Today AGA Reading Room article reviews the effects of a sustained viral response on outcomes of patients with HCV.

Registration Open for 2017 AGA Postgraduate Course

Jan. 11, 2017

Early access to registration is open for AGA members. Secure your spot a week before general registration opens and save $75.

2017 AGA Postgraduate Course Online Sessions

Jan. 4, 2017

Pre-order the on-demand online sessions from the 2017 AGA Postgraduate Course: The Full Scope of GI Advances to learn key treatment advances that you can immediately implement in your practice.